Vektor Medical's vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care
SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes.
vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less than a minute. Clinical studies have shown that use of vMap is associated with a reduction in procedure time, which may reduce fluoroscopy time and improve safety. vMap integrates seamlessly into existing systems, making it an increasingly valuable solution for electrophysiologists seeking greater efficiency and performance without compromise. vMap is now in use at over 20 hospitals throughout the United States.
"vMap has become an integral part of how I care for patients," said Dr. Anish Amin, Section Chief, Electrophysiology, OhioHealth Heart and Vascular. "It's efficient, non-invasive, and delivers insights that enhance every stage of the ablation process from planning through execution. With vMap, I can pinpoint arrhythmia sources faster with greater confidence, treat more accurately, and potentially reduce repeat interventions for patients. I'm looking forward to enrolling patients in the IMPRoVED-AF study, which will further validate the clinical impact of this technology and its potential to transform how we approach AF ablation."
As adoption of pulsed field ablation (PFA) accelerates, the need for accurate, accessible data is greater than ever. vMap can enhance the impact of PFA by helping EPs identify optimal ablation targets before entering the lab and reiteratively during the procedure. With vMap's rapid, non-invasive ECG-based driver localization, physicians have more information to better target areas of interest, supporting more efficient procedures and unlocking the full potential of PFA.
"This milestone represents meaningful momentum," said Robert Krummen, CEO of Vektor Medical. "With every procedure, physicians are leveraging vMap's rapid, non-invasive insights to make informed decisions and streamline care. We're seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care."
The vMap system is FDA-cleared and commercially available in the United States. As clinical use continues to expand, Vektor Medical remains focused on advancing the future of arrhythmia care through clinical innovation, strategic partnerships, and physician impact.
To learn more about Vektor Medical, vMap technology, or to request a clinical or strategic briefing, visit www.vektormedical.com and connect with us on LinkedIn and X.
About Vektor Medical
Headquartered in San Diego, Vektor Medical is redefining how arrhythmias are understood and treated. The company developed vMap®, the only FDA-cleared, non-invasive technology that uses standard 12-lead ECG data to localize arrhythmia source locations across all four chambers of the heart. By helping physicians identify arrhythmia drivers more quickly and with greater accuracy, Vektor is improving outcomes, enhancing efficiencies, and accelerating access to effective treatment strategies. To learn more, visit www.vektormedical.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250723882070/en/
Contacts
Media Contact Stacey HolifieldLevitate(617) 233-3873vektor@levitatenow.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
UnitedHealth Group (UNH) Responds to the Department of Justice
UnitedHealth Group Incorporated (NYSE:UNH) is one of the top low volatility healthcare stocks to buy now. On July 24, UnitedHealth Group Incorporated (NYSE:UNH) released a statement responding to the Department of Justice after a review of the media reports about investigations into specific aspects of its involvement in the Medicare program. A senior healthcare professional giving advice to a patient in a clinic. UnitedHealth Group Incorporated (NYSE:UNH) stated that it has now begun complying with the formal criminal and civil requests from the Department, and has 'full confidence in its practices and is committed to working cooperatively with the Department throughout this process'. It added that UnitedHealth Group Incorporated (NYSE:UNH) has a historical record of 'responsible conduct and effective compliance,' with independent CMS audits showing that its practices are ranked 'among the most accurate in the industry.' Management stated that after a decade-long civil challenge by the Department to aspects of the company's Medicare Advantage business, 'a court-appointed Special Master concluded there was no evidence to support claims of wrongdoing'. UnitedHealth Group Incorporated (NYSE:UNH) has launched its own initiative to provide confidence and transparency to stakeholders, focusing on conducting 'third-party reviews of policies, practices, and associated processes and performance metrics for risk assessment coding, managed care practices, and pharmacy services.' UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments, which have solid operations. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Medscape
3 minutes ago
- Medscape
Cancer Care Costs High Among Privately Insured Patients
TOPLINE: A recent analysis found that privately insured US patients with newly diagnosed cancer, especially those with more advanced disease, had 'substantial out-of-pocket costs.' Monthly out-of-pocket costs among these patients increased by a mean of almost $600, on average, but increased to nearly $720 per month for those with stage IV disease. METHODOLOGY: Out-of-pocket costs for cancer care in the US are rising, but most research has focused on Medicare beneficiaries. It's important to understand privately insured patients' financial burdens, especially with cancer rates growing among younger Americans. Researchers conducted a retrospective study of 19,656 patients with cancer, using a dataset that links claims from a large private insurer to the Surveillance, Epidemiology, and End Results cancer registry. Overall, 74.1% had breast cancer, 14.5% had colorectal cancer, and 11.4% had lung cancer. Analyses also included 26,502 individuals without cancer who were assigned pseudo – diagnosis date. Monthly out-of-pocket costs (copays, co-insurance, and deductibles) were calculated from claims and inflation-adjusted to 2024 US dollars. TAKEAWAY: After a cancer diagnosis, monthly out-of-pocket costs rose by $592, on average. Those added costs increased with disease stage, from $462 per month for stage 0 cancer to $720 per month for stage IV cancer. Out-of-pocket costs spiked in the month of diagnosis and remained elevated for 6 months compared with those in individuals without cancer — totaling an average of $4145 in cumulative additional costs (over 7 months). IN PRACTICE: 'In this cohort study, patients with private insurance were found to have high OOPCs [out-of-pocket costs] after an incident diagnosis of cancer, and those with the most advanced cancer had the highest OOPCs,' the authors wrote. 'The variability in OOPCs based on cancer stage underscores the need for policies such as paid sick leave, that address both insurance continuity and financial assistance, especially for patients with more advanced cancer.' SOURCE: This study, led by Liam Rose, PhD, Stanford University School of Medicine, Palo Alto, California, was published online in JAMA Network Open. LIMITATIONS: Differential insurance attrition could have affected the results: Patients with stage IV cancer were most likely to drop their coverage. The study could only capture direct medical costs, which misses other potential financial burdens, such as lost income and travel expenses. DISCLOSURES: This study received funding support through a grant from the American Cancer Society. One author reported receiving grants from the Department of Veterans Affairs and National Institutes of Health during the conduct of the study. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Entrepreneur
3 minutes ago
- Entrepreneur
Meta Appoints Ex-OpenAI Scientist Shengjia Zhao to Lead New Superintelligence Lab
Zhao, previously a research scientist at OpenAI, played a pivotal role in creating GPT-4 and various lighter models such as version 4.1 and o3. He is among at least eight researchers who have recently transitioned from OpenAI to Meta. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Meta Platforms has appointed Shengjia Zhao, a leading figure in the development of OpenAI's ChatGPT, as chief scientist of its newly launched Superintelligence Lab. This high-profile move marks a significant step in Meta's accelerating drive to position itself at the forefront of advanced artificial intelligence. CEO Mark Zuckerberg shared the announcement on Friday through Threads. He said Zhao will guide the lab's scientific direction and collaborate closely with both Zuckerberg and Meta's Chief AI Officer Alexandr Wang. Wang joined the company earlier this year after Meta took a substantial stake in his former company, Scale AI. Zhao, previously a research scientist at OpenAI, played a pivotal role in creating GPT-4 and various lighter models such as version 4.1 and o3. He is among at least eight researchers who have recently transitioned from OpenAI to Meta. The influx of talent signals Meta's intent to rapidly close the distance with competitors in the race toward building artificial general intelligence. The creation of the Superintelligence Lab is part of Meta's broader efforts to establish a premier AI research division. The lab is distinct from FAIR, Meta's long-standing AI unit led by deep learning pioneer Yann LeCun. While FAIR has focused on foundational research, the new lab aims to develop what Zuckerberg has described as full general intelligence. Zuckerberg also confirmed that Meta plans to open-source the work produced by the Superintelligence Lab. This strategy has drawn mixed reactions within the AI community, with some praising the transparency and others warning of risks linked to such openness. Meanwhile, Meta's recruitment campaign has unsettled OpenAI. Internal messages leaked this month revealed OpenAI Chief Research Officer Mark Chen comparing Meta's tactics to "someone breaking into our home and stealing something." In response, OpenAI is reportedly reassessing its compensation practices and offering staff additional time off to curb further departures. OpenAI CEO Sam Altman has publicly criticised what he views as profit-driven hiring practices. He alleged that Meta has lured researchers with offers reaching USD 100 million in signing bonuses, a claim dismissed as exaggerated by Meta's Chief Technology Officer Andrew Bosworth. However, reports of even higher offers, including an unverified USD 1.25 billion compensation package over four years, illustrate the escalating competition for elite AI talent. While Altman argues that OpenAI's mission-focused approach offers a stronger long-term foundation, others in the industry see Meta's strategy as justified. Google DeepMind's CEO Demis Hassabis called the hiring surge a rational response given Meta's desire to catch up. With over USD 14 billion invested in AI infrastructure and partnerships, Meta is making its intentions clear. The addition of Zhao and other key hires underscores the company's determination to lead—not just follow—the next wave of AI development.
